Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis
Annals of the Rheumatic Diseases · 2026-06 · 85 (6) · 1039-1054
DOI: 10.1016/j.ard.2026.03.020 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of the Rheumatic Diseases, 2026-06. Verfasst von Victoria Konzett und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: victoria.konzett@meduniwien.…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Glucocorticoids, Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Alliance of Associations for Rheumatology, OpenAI.
Abstract (Originalsprache)
OBJECTIVES: This systematic literature review (SLR) updated evidence on the efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs) to inform the 2025 update of the European Alliance of Associations for Rheumatology (EULAR) management recommendations for rheumatoid arthritis (RA). METHODS: Medline (PubMed), Embase (OVID), Cochrane Central Register of Controlled Trials, and Web of Science were searched for randomised controlled trials (RCTs) of conventional-synthetic, biological, and targeted-synthetic DMARDs (csDMARDs, bDMARDs, tsDMARDs), as well as GCs and biosimilars, published from 14 January 2022 to 22 January 2025. Additional searches on DMARDs, GCs, and antifibrotics for RA-associated interstitial lung disease (RA ILD), and on DMARDs and GCs for preventing RA in at-risk individuals, were conducted from database inception to 22 January 2025. RESULTS: A total of 12,567 references were identified; 390 full-texts were reviewed, and 72 studies were included. Phase 3-4 RCTs evaluated csDMARDs (hydroxychloroquine, iguratimod, leflunomide, and methotrexate), bDMARDs (abatacept, otilimab, and ozoralizumab), and tsDMARDs (ivarmacitinib, peficitinib, and tofacitinib). Twelve novel compounds were assessed in phase 2 RCTs, and 3 articles investigated GCs. Strategic trials compared conventional therapies with bDMARD- or tsDMARD-based strategies and explored precision-medicine approaches such as synovial biopsy-guided treatment and therapeutic drug monitoring. Additional evidence addressed DMARD tapering. Two RCTs assessed antifibrotics (nintedanib and pirfenidone) for RA ILD, and 7 studies evaluated DMARDs for RA prevention in at-risk populations. CONCLUSIONS: This SLR, together with the safety review, informed the 2025 update of the EULAR RA management recommendations. Although few phase 3 trials on novel agents were available, strategic and head-to-head studies provided important insights that enabled further refinement of the established treatment algorithm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Electronic address: victoria.konzett@meduniwien.ac.at.
- MRC Lifecourse Epidemiology Centre Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
- Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- NIHR Southampton Clinical Research Facility, University Hospital Southampton, Southampton, UK.
- Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
- School of Public Health, Oregon Health & Science University, Portland, Oregon, USA.
Förderung
- European Alliance of Associations for Rheumatology
- OpenAI
Zitieren
APA
Konzett, V., Laskou, F., Smolen, J. S., Edwards, C. J., Aletaha, D., van der Heijde, D., Winthrop, K. L., Takeuchi, T., Caporali, R., Verschueren, P., Pope, J. E., Hyrich, K. L., de Souza, S., Stamm, T. A., Primdahl, J., Schoones, J. W., Landewé, R. B. M., & Kerschbaumer, A. (2026). Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 85(6), 1039-1054. https://doi.org/10.1016/j.ard.2026.03.020
Vancouver
Konzett V, Laskou F, Smolen JS, Edwards CJ, Aletaha D, van der Heijde D, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases. 2026;85(6):1039-1054. doi:10.1016/j.ard.2026.03.020
BibTeX
@article{Konzett2026,
author = {Konzett, Victoria and Laskou, Faidra and Smolen, Josef S and Edwards, Christopher J and Aletaha, Daniel and van der Heijde, Désirée and Winthrop, Kevin L and Takeuchi, Tsutomu and Caporali, Roberto and Verschueren, Patrick and Pope, Janet E and Hyrich, Kimme L and de Souza, Savia and Stamm, Tanja A and Primdahl, Jette and Schoones, Jan W and Landewé, Robert B M and Kerschbaumer, Andreas},
title = {Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {6},
pages = {1039--1054},
doi = {10.1016/j.ard.2026.03.020}
}
EUVIMED